EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prolonged chimeric antigen receptor‐T apheresis to infusion time is associated with inferior outcomes in diffuse large B‐cell lymphoma

Suguru Morimoto, Tomoyasu Jo iD, Toshio Kitawaki iD, Takashi Sakamoto, Chisaki Mizumoto, Junya Kanda iD, Momoko Nishikori iD, Kouhei Yamashita, Miki Nagao, Akifumi Takaori-Kondo, Yasuyuki Arai iD

British Journal of Haematology · 2025-10 · 207 (4) · 1484-1494

DOI: 10.1111/bjh.70090 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 11.08.2025. Verfasst von Suguru Morimoto und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Kyoto University Hospital, Kyoto, Japan. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Blood Component Removal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T‐cell therapy is effective for relapsed/refractory (r/r) diffuse large B‐cell lymphoma (DLBCL). However, delays between apheresis and infusion frequently occur due to limited facility capacity and prolonged bridging therapy, and the clinical impact of such delays remains uncertain. We retrospectively analysed R/R DLBCL patients who underwent CAR‐T‐cell therapy at Kyoto University Hospital. Among 90 patients, the median apheresis to infusion interval was 66 days (range, 28–203). Patients were categorized into delayed (≥66 days) and non‐delayed (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseImmunotherapy, AdoptiveReceptors, Chimeric AntigenBlood Component RemovalHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultAged, 80 and overTreatment OutcomeTime FactorsPrognosis

Stichwörter der Autor:innen

bridging therapychimeric antigen receptor T‐cell therapydiffuse large B‐cell lymphoma

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Hematology, Kyoto University Hospital, Kyoto, Japan.
  • Department of Cytotherapy, Kyoto University Hospital, Kyoto, Japan.
  • Center for Research and Application of Cellular Therapy, Kyoto University Hospital, Kyoto, Japan.
  • Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

ORCID-Profile: Tomoyasu Jo, Toshio Kitawaki, Junya Kanda, Momoko Nishikori, Yasuyuki Arai

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Morimoto, S., Jo, T., Kitawaki, T., Sakamoto, T., Mizumoto, C., Kanda, J., Nishikori, M., Yamashita, K., Nagao, M., Takaori-Kondo, A., & Arai, Y. (2025). Prolonged chimeric antigen receptor‐T apheresis to infusion time is associated with inferior outcomes in diffuse large B‐cell lymphoma. British Journal of Haematology, 207(4), 1484-1494. https://doi.org/10.1111/bjh.70090

Vancouver

Morimoto S, Jo T, Kitawaki T, Sakamoto T, Mizumoto C, Kanda J, et al. Prolonged chimeric antigen receptor‐T apheresis to infusion time is associated with inferior outcomes in diffuse large B‐cell lymphoma. British Journal of Haematology. 2025;207(4):1484-1494. doi:10.1111/bjh.70090

BibTeX
@article{Morimoto2025,
  author = {Morimoto, Suguru and Jo, Tomoyasu and Kitawaki, Toshio and Sakamoto, Takashi and Mizumoto, Chisaki and Kanda, Junya and Nishikori, Momoko and Yamashita, Kouhei and Nagao, Miki and Takaori-Kondo, Akifumi and Arai, Yasuyuki},
  title = {Prolonged chimeric antigen receptor‐T apheresis to infusion time is associated with inferior outcomes in diffuse large B‐cell lymphoma},
  journal = {British Journal of Haematology},
  year = {2025},
  volume = {207},
  number = {4},
  pages = {1484--1494},
  doi = {10.1111/bjh.70090}
}
Kostenlos starten →